Product InformationRegistration Status: Active
DAUNOBLASTINA FOR INJECTION 20mg/VIAL is approved to be sold in Singapore with effective from 1988-05-05. It is marketed by PFIZER PTE LTD, with the registration number of SIN00774P.
This product contains Daunorubicin 20mg/vial in the form of INJECTION, POWDER, FOR SOLUTION. It is approved for INTRAVENOUS use.
This product is manufactured by Actavis Italy S.p.A. in ITALY.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. [PubChem]
For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
Mechanism of Action
Daunorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Daunorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.
LD50=20 mg/kg (mice, IV); LD50=13 mg/kg (rat, IV)
(+)-Daunomycin | (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione | Acetyladriamycin | Daunomycin | Daunorubicin | Daunorubicina | Daunorubicine | Daunorubicinum | Leukaemomycin C | Rubidomycin | Daunorubicin |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.